Home > Haematology > EHA 2020 > DEC10-VEN superior to intensive chemotherapy in high-risk AML

DEC10-VEN superior to intensive chemotherapy in high-risk AML

10-day decitabine and venetoclax (DEC10-VEN) showed superior outcomes compared with intensive chemotherapy in older patients with acute myeloid leukaemia (AML) in a propensity score matching analysis. Benefits were most pronounced in patients at high risk of treatment-related mortality (TRM).

The results of the phase 2 trial were presented by Dr Abhishek Maiti (University of Texas MD Anderson Cancer Centre, USA) [1]. This study addressed the question of how venetoclax + decitabine compared with intensive chemotherapy in patients stratified by TRM, as assessed by a validated TRM risk model [2]. The primary endpoint was overall response rate (ORR). Key secondary outcomes included duration of response, disease-free survival, and overall survival (OS).

Frontline AML patients (n=255) received either DEC10-VEN comprising 10 days decitabine 20 mg/m2 with daily venetoclax for induction...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on